Absci Corp
ABSIHeld by 7 specialist biotech funds
High Convergence7 funds opened new positions. Next phase2 readout (ABS-201 IV Single Dose): Jul 2028. Short interest: 25.6% of float.
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.